Current status of tyrosine hydroxylase in management of Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 450-455

  Feve, Annaik Petithomme ^a  

^a Léopold Bellan Hospital   (France)

Author keywords

Dopamine synthesis; Gene therapy; Neuroprotection; Parkinson's disease; Tyrosine hydroxylase; synuclein

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOVIRUS VECTOR; ALPHA SYNUCLEIN; CATECHOLAMINE; DOPAMINE; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINE NERVE CELL; DOPAMINE METABOLISM; DRUG TARGETING; DYSTONIA; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENE THERAPY; INTERNEURON; INTRACELLULAR SIGNALING; LEWY BODY; MISSENSE MUTATION; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84862581390     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792910     Document Type: Article

References (64)

1. de Lau, L.; Breteler, M. Epidemiology of PD. Lancet Neurol., 2006 5, 525-535.
2. Chaudhuri, R.; Schapira, A. Non-motor symptoms of PD: dopaminergic pathophysiology and treatment. Lancet Neurol., 2009, 8, 464-474.
3. Feve, A.P.; Fenelon, G.; Wallays, C.; Remy, P.; Guillard, A. Axial motor disturbances after lesions of the globus pallidus. Mov. Disord., 1993, 8(3), 321-326.
4. Feve, A.; Bathien, N.; Rondot, P. Abnormal movement related potentials in patients with lesions of basal ganglia and anterior thalamus. J. Neurol. Neurosurg. Psychiatry, 1994, 57(1) 100-104.
5. Bergman, H.; Deuschl, G. Pathophysiology of Parkinson's disease: from clinical to basic neuroscience and back. Mov. Disord., 2002, 17(Suppl 3), S28-S40.
6. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl. J. Med., 2004, 351, 2498-2508.
7. Feve, A. Chronic administration of L-Dopa affects the movement related cortical potentials of patients with Parkinson's disease. Clin. Neuropharmacol., 1992, 15(2), 100-108.
8. Feve, A.; Bathien, N.; Rondot, P. Changes in movement related cortical potentials in Parkinson's patients bedfore and after treatment with levodopa. Neurophysiol. Clin., 1991, 21(2) 105-119.
9. Fahn, S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch. Neurol., 1999, 56, 529-535.
10. Ichinose, H.; Suzuki, T.; Inagaki, H.; Ohye, T.; Nagatsu, T. Molecular genetics of dopa responsive dystonia. Biol. Chem., 1999, 380(12), 1355-1364.
11. Olanow, C.; Stern, M.; Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 2009, 72(Suppl 4), S1-S136.
12. Calne, D.B.; Karoum, F.; Ruthven, C.R.; Sandler, M. The metabolism of orally administered L-DOPA in Parkinsonism. Br. J. Pharmacol., 1969, 37, 57-68.
13. Kalinderi, K.; Fidani, L.; Katsarou, Z.; Bostanjopoulos, S. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. Int. J. Clin. Pract., 2011, 65(12),1289-1294.
14. Goodman LS, Gilman A. Goodman & Gilman's the pharmacological basis of therapeutics. ed. New York: McGraw- Hill, 2006.
15. Samii, A.; Nutt, JG.; Ransom, B.R. Parkinson's disease. Lancet, 2004, 363, 1783-1793.
16. Haavik, J.; Toska, K. Tyrosine hydroxylase and Parkinson'sdisease. Mol. Neurobiol., 1998, 16, 285-309.
17. Nagatsu, T.; Sawada, M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J. Neural Transm. Suppl., 2007, 72, 113-120.
18. Chase, T.N.; Engber, T.M.; Mouradian, M.M. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease. Adv. Neurol., 1993, 60, 181-185.
19. Stocchi, F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15(Suppl.1), S9-S15.
20. Song, D.D.; Haber, S.N. Striatal response to partial dopaminergic lesion: evidence for compensatory sprouting. J. Neurosci., 2000, 20, 5102-5114.
21. Betarbet, E.; Turner, R.; Chockkan, V.; DeLong, M.R.; Allers, K.A.; Walters, J.; Levey, A.I.; Greenamyre, J.T. Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci., 1997, 17, 6761-6768.
22. Bezard, E.; Gross, C.E.; Brotchie, J.M. Presymptomatic compensation in Parkinson's disease is not dopamine mediates. Trends Neurosci., 2003, 26, 215-221.
23. Calabresi, P.; Picconi, B.; Tozzi, A.; Di Filippo, M. Dopamine mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci., 2007, 30, 211-219.
24. Ungerstedt, U. 6 hydroxy dopamine induced degeneration o central monoamine neurons. Eur. J. Pharmacol., 1968, 5, 107-110.
25. Lee, C.S.; Sauer, H.; Bjorklund, A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6 hydroxydopamine in the rat. Neuroscience, 1996, 72, 641-653.
26. Xu, Z.; Cawthon, D.; Mac Castlain, K.A.; Slikker, W., Jr.; Ali, S.F. Selective alterations of gene expression in mice induced MPTP. Synapse, 2005, 55, 45-51.
27. Blume, S.R.; Cass D.K.; Tseng K.Y. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTPinduced Parkinsonism. Exp. Neurol., 2009, 219(1), 208-211.
28. Prediger, R.D.S.; Aguiar, A.S., Jr.; Rojas-Mayorquin, A.E.; Figueiredo, C.P.; Matheus, F.C.; Ginestet, L.; Chevarin, C.; Del Bel, E.; Mongeau, R.; Hamon, M.; Lanfumey, L.; Raisman-Vozari, R. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57Bl/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res., 2010, 17(2), 114-129.
29. Meredith, G.E.; Kang, U.J. Behavioral models of Parkinson's disease: a new look at an old problem. Mov. Disord., 2006, 21(10),1595-1606.
30. Goldberg, N.R.S.; Meshul C.K. Effects of intermittent washout periods on progressive lesioning of the nigro striatal pathway with MPTP. Neuroscience, 2011, 182, 203-207.
31. Capitelli, C.; Sereniki, A.; Meira Santos Lima, M.; Reksidler, A.B.; Tufik, S.; Barbato Frazão, B.A. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur. J. Pharmacol., 2008, 594, 101-108.
32. Muramatsu, S.; Wang, L.; Ikeguchi, K.; Fujimoto, K.; Nakano, I.; Ozawa, K. Ecombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality. J. Neurol., 2002,249(Suppl 2), 36-40.
33. Horellou, P.; Vigne, E.; Castel, M.N.; Barneoud, P.; Colin, P.; Perricaudet, M.; Delaere, P.; Mallet, J. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport, 1994, 6, 49-53.
34. Cao, L.; Zhao, Y.C.; Jiang, Z.H.; Xu, D.H.; Liu, Z.G.; Chen, S.D.; Liu, X.Y.; Zheng, Z.C. Long-term phenotypic correction of rodent hemiparkinsonism by gene therapy using genetically modified myoblasts. Gene Ther., 2000, 7, 445-449.
35. Schwarz, E.J.; Alexander, G.M.; Prockop, D.J. Azizi, S.A. Multipotential marrow stromal cells transduced to produce LDOPA: Engraftment in a rat model of Parkinson disease. Hum. Gene Ther., 1999, 10, 2539-2549.
36. Fan, D.S.; Ogawa, M.; Fujimoto, K.I.; Ikeguchi, K.; Ogasawara, Y.; Urabe, M.; Nishizawa, M.; Nakano, I.; Yoshida, M.; Nagatsu, I.; Ichinose, H.; Nagatsu, T.; Kurtzman, G.J.; Ozawa, K. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine- hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther., 1998, 9, 2527-2535.
37. Nagatsu, T.; Ichinose, H. GTP cyclohydrolase I gene, dystonia, juvenile parkinsonism, and Parkinson's disease. J. Neural Transm., 1997, Suppl. 49, 203-209.
38. Leff, S.E.; Rendahl, K.G.; Spratt, S.K.; Kang, U.J.; Mandel, R.J. In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTP cyclohydrolase I with tyrosine hydroxylase. Exp. Neurol., 1998, 151, 249-264.
39. Kirik, D.; Georgievska, B.; Burger, C.; Winkler, C.; Muzyczka, N.; Mandel, R.J. Bjorklund, A. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAVV-mediated gene transfer. Proc. Natl. Acad. Sci. USA, 2002, 99, 4708-4713.
40. Muramatsu, S.; Fujimoto, K.; Ikeguchi, K.; Shizuma, N.; Kawasaki, K.; Ono, F.; Shen, Y.; Wang, L.; Mizukami, H.; Kume, A.; Matsumura, M.; Nagatsu, I.; Urano, F.; Ichinose, H.; Nagatsu, T.; Terao, K.; Nakano, I.; Ozawa, K. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adenoassociated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther., 2002, 13, 345-354.
41. Shen, Y.; Muramatsu, S.I.; Ikeguchi, K.I.; Fujimoto, K.I.; Fan, D.S.; Ogawam Mizukami, H; Usabe, M.; Kume, A.; Nagatsu, I.; Urano, F.; Suzuki, T.; Ichinose, H.; Nagatsu, T.; Monahan, J.; Nakano, I.; Ozawa K. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic L amino acid decarboxylase, and GTP cyclohydrolase I for gene therapy in Parkinosn's disease. Hum. Gene Ther., 2000, 11, 1509-1519.
42. Carlsson, T.; Björklund, T.; Kirik, D. Restoration of the striatal dopamine synthesis for parkinson's disease: viral vector-mediated enzyme replacement strategy. Curr. Gene Ther., 2007, 7, 109-120.
43. Leriche, L.; Bjorklund, T.; Breysse, N.; Besret, L.; Gregoire, M.C.; Carlsson, T. Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J. Neurosci., 2009, 29, 1544-1545.
44. Reimsnider, S.; Manfredsson, F.P.; Muzyczka, N.; Mandel, R.J. Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol. Ther., 2007, 15, 1504-1511.
45. Bjorklund, T.; Carlsson, T.; Cederfja, E.A.; Carta, M.; Kirik, D. Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain, 2010, 133, 496-511.
46. Haavik, J.; Toska, K. Tyrosine hydroxylase and Parkinson's disease. Mol. Neurobiol., 1998, 16, 285-309.
47. Hertz, M.; Østergaard, K.; Juncker, I.; Pedersen, S.; Romstad, A.; Møller, L.B.; Güttler, F.; Dupont, E. Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's Disease. Eur. J. Neurol., 2006, 13, 385-390.
48. Bademci, G.; Edwards, T.L.; Torres, A.L.; Scott, W.S.; Züchner, S.; Martin, E.R.; Vance, J.M.; Wang, L. A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease. Hum. Mut., 2010, 31, E1767-E1771.
49. Swaans, R.J.; Rondot, P.; Renier, W.O.; Van Den Heuvel, L.P.; Steenbergen-Spanjers, G.C.; Wevers, R.A. Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism. Ann. Hum. Genet., 2000, 64, 25-31.
50. Ludecke, B.; Knappskog, P.M.; Clayton, P.T.; Surtees, R.A.; Clelland, J.D.; Heales, S.J.; Brand, M.P.; Bartholomé, K.; Flatmark, T. Recessively inherited l-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum. Mol. Genet., 1996, 5, 1023-1028.
51. Kunugi, H.; Kawada, Y.; Hattori, M.; Ueki, A.; Otsuka, M.; Nanko, S. Association study of structural mutations of the tyrosine hydroxylase gene with schizophrenia and Parkinson's disease. Am. J. Med. Genet., 1998, 81, 131-133.
52. Segawa, M.; Hosaka, A.; Miyagawa, F.; Nomura, Y.; Imai, H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv. Neurol., 1976, 14, 215-233.
53. Clot, F.; Grabli, D.; Cazeneuve, C.; Roze, E.; Castelnau, P.; Chabrol, B.; Landrieu, P.; Nguyen, K.; Ponsot, G.; Abada, M.; Doummar, D.; Damier, P.; Gil, R.R.; Thobois, S.; Ward, A.; Hutchinson, M.; Toutain, A.; Picard, F.; Camuzat, A.; Fedirko, E.; San, C.; Bouteiller, D.; Le Guern, E.; Durr, A.; Vidailhet, M.; Brice, A. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain, 2009, 132, 1753-1763.
54. Ramsey, A.J.; Fitzpatrick, P.F. Effects of phosphorylation on binding of catecholamines to tyrosine hydroxylase: specificity and thermodynamic. Biochemistry, 2000, 39, 773-777.
55. Perez, R.G.; Waymire, J.C.; Lin, E.; Liu, J.J.; Guo, F.; Zigmond, M.J.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci., 2002, 22(8), 3090-3099.
56. Kuhn, D.M.; Geddes, T.J. Tetrahydrobiopterin prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide. Mol. Pharmacol., 2003, 64, 946-953.
57. Tsang, A.H.K.; Chung, K.K.K.; Oxydative and nitrosative stress in Parkinson' s disease. Mol. Basis Dis., 2009, 1792, 643-650.
58. Pakkenberg, B.; Møller, A.; Gundersen, H.J.; Mouritzen Dam, A.; Pakkenberg, H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with unbiased stereological method. J. Neurol. Neurosurg. Psychiatry, 1991, 54, 30-33.
59. Lourenco Venda, L.; Cragg, S.J.; Buchman, V.L.; Wade-Martins, R. α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci., 2010, 33, 559-568.
60. Yu, S.; Zuo, X.; Li, Y.; Zhang, C.; Zhou, M.; Zhang, Y.A.; Uéda, K.; Chan, P. Inhibition of tyrosine hydroxylase expression inalphasynuclein- transfected dopaminergic neuronal cells. Neurosci. Lett.; 2004, 367, 34-39.
61. Peng, X.; Tehranian, R.; Dietrich, P.; Stefanis, L.; Perez, R.G. Alpha-synuclein activation of proteinphosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell Sci., 2005, 118, 3523-3530.
62. Gao, N.; Ly, Y.H.; Li, X.; Yu, S.; Fu, G.L.; Chen, B. Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene. Neurosci. Bull., 2007, 23, 53-57.
63. Liu, D.; Jin, L.; Wang, H.; Zhao, H.; Zhao, C.; Lu, L.; Wu, B.; Yu, S.; Chan, P.; Li, Y.; Yang, H. Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem. Res., 2008, 7, 1401-1409.
64. Daubner, S.C.; Le, T.; Wang, S. Tyrosine hydroylase and regulation of dopamine synthesis. Arch. Biochem. Biophys., 2011, 508, 1-12.